|
US5106742A
(en)
*
|
1987-03-31 |
1992-04-21 |
Wall Monroe E |
Camptothecin analogs as potent inhibitors of topoisomerase I
|
|
US5053512A
(en)
*
|
1987-04-14 |
1991-10-01 |
Research Triangle Institute |
Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
|
|
US5122526A
(en)
*
|
1987-03-31 |
1992-06-16 |
Research Triangle Institute |
Camptothecin and analogs thereof and pharmaceutical compositions and method using them
|
|
US4981968A
(en)
*
|
1987-03-31 |
1991-01-01 |
Research Triangle Institute |
Synthesis of camptothecin and analogs thereof
|
|
US5244903A
(en)
*
|
1987-03-31 |
1993-09-14 |
Research Triangle Institute |
Camptothecin analogs as potent inhibitors of topoisomerase I
|
|
US5227380A
(en)
*
|
1987-03-31 |
1993-07-13 |
Research Triangle Institute |
Pharmaceutical compositions and methods employing camptothecins
|
|
US4894456A
(en)
*
|
1987-03-31 |
1990-01-16 |
Research Triangle Institute |
Synthesis of camptothecin and analogs thereof
|
|
US5364858A
(en)
*
|
1987-03-31 |
1994-11-15 |
Research Triangle Institute |
Camptothecin analogs as potent inhibitors of topoisomerase I
|
|
US5049668A
(en)
*
|
1989-09-15 |
1991-09-17 |
Research Triangle Institute |
10,11-methylenedioxy-20(RS)-camptothecin analogs
|
|
US5122606A
(en)
*
|
1987-04-14 |
1992-06-16 |
Research Triangle Institute |
10,11-methylenedioxy camptothecins
|
|
US5180722A
(en)
*
|
1987-04-14 |
1993-01-19 |
Research Triangle Institute |
10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
|
|
US5340817A
(en)
*
|
1987-04-14 |
1994-08-23 |
Research Triangle Institute |
Method of treating tumors with anti-tumor effective camptothecin compounds
|
|
US4939255A
(en)
*
|
1987-06-24 |
1990-07-03 |
Daiichi Pharmaceutical Co., Ltd. |
Hexa-cyclic camptothecin derivatives
|
|
US4943579A
(en)
*
|
1987-10-06 |
1990-07-24 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Water soluble prodrugs of camptothecin
|
|
US5004758A
(en)
*
|
1987-12-01 |
1991-04-02 |
Smithkline Beecham Corporation |
Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
|
|
JPH0615547B2
(ja)
*
|
1988-01-20 |
1994-03-02 |
株式会社ヤクルト本社 |
新規なカンプトテシン誘導体
|
|
US5225404A
(en)
*
|
1989-11-06 |
1993-07-06 |
New York University |
Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
|
|
US5552154A
(en)
*
|
1989-11-06 |
1996-09-03 |
The Stehlin Foundation For Cancer Research |
Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
|
|
US5658920A
(en)
*
|
1991-01-16 |
1997-08-19 |
Daiichi Pharmaceutical Co., Ltd. |
Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
|
|
US6407115B1
(en)
*
|
1991-01-16 |
2002-06-18 |
Daiichi Pharmaceutical Co., Ltd. |
Hexa-cyclic compound
|
|
ATE247471T1
(de)
|
1991-11-15 |
2003-09-15 |
Smithkline Beecham Corp |
Cisplatin und topotecan enthaltende zusammensetzung als antitumor.
|
|
US6080751A
(en)
*
|
1992-01-14 |
2000-06-27 |
The Stehlin Foundation For Cancer Research |
Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
|
|
US5391745A
(en)
*
|
1992-07-23 |
1995-02-21 |
Sloan-Kettering Institute For Cancer Research |
Methods of preparation of camptothecin analogs
|
|
US5446047A
(en)
*
|
1992-07-23 |
1995-08-29 |
Sloan-Kettering Institute For Cancer Research |
Camptothecin analogues
|
|
AP9300587A0
(en)
*
|
1992-11-12 |
1995-05-05 |
Glaxo Inc |
Water soluble camptothecin derivatives.
|
|
US5447936A
(en)
*
|
1993-12-22 |
1995-09-05 |
Bionumerik Pharmaceuticals, Inc. |
Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
|
|
GB9402934D0
(en)
*
|
1994-02-16 |
1994-04-06 |
Erba Carlo Spa |
Camptothecin derivatives and process for their preparation
|
|
US5468754A
(en)
*
|
1994-04-19 |
1995-11-21 |
Bionumerik Pharmaceuticals, Inc. |
11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
|
|
US5597829A
(en)
*
|
1994-05-09 |
1997-01-28 |
Bionumerik Pharmaceuticals, Inc. |
Lactone stable formulation of camptothecin and methods for uses thereof
|
|
US5604233A
(en)
*
|
1994-04-28 |
1997-02-18 |
Bionumerik Pharmaceuticals, Inc. |
Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
|
|
US5646159A
(en)
*
|
1994-07-20 |
1997-07-08 |
Research Triangle Institute |
Water-soluble esters of camptothecin compounds
|
|
US5614529A
(en)
*
|
1994-09-22 |
1997-03-25 |
Research Triangle Institute |
Inhibition of plasmodia parasites by camptothecin compounds
|
|
US6177439B1
(en)
|
1995-06-06 |
2001-01-23 |
Reddy's Research Foundation |
Water soluble analogues of 20(S)-camptothecin
|
|
US5972955A
(en)
*
|
1995-06-06 |
1999-10-26 |
Dr. Reddy's Research Foundation |
Water soluble C-ring analogues of 20(S)-camptothecin
|
|
US6214836B1
(en)
|
1995-06-06 |
2001-04-10 |
Dr. Reddy's Research Foundation |
Water soluble analogues of 20(S)-camptothecin
|
|
EP0835303A4
(en)
*
|
1995-06-07 |
2000-09-13 |
Univ Jefferson |
Anti-fungal agents and methods of identifying and using the same
|
|
AU7732996A
(en)
*
|
1995-11-22 |
1997-06-11 |
Research Triangle Institute |
Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
|
|
US6395541B1
(en)
|
1996-05-23 |
2002-05-28 |
The Rockefeller University |
Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
|
|
KR100516593B1
(ko)
*
|
1996-08-19 |
2005-09-22 |
바이오누머릭 파마슈티칼스, 인코포레이티드 |
고 친유성 캠프토테신 유도체
|
|
WO1998037892A1
(en)
*
|
1997-02-27 |
1998-09-03 |
Pharmacia & Upjohn Company |
Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea
|
|
JP3046258B2
(ja)
*
|
1997-04-11 |
2000-05-29 |
株式会社ヤクルト本社 |
１−クロロカルボニル−４−ピペリジノピペリジンまたはその塩酸塩の製造方法
|
|
ID23424A
(id)
|
1997-05-14 |
2000-04-20 |
Bayer Ag |
Glikokonjugat dari 20(s)-kamptotesin
|
|
US6214821B1
(en)
|
1998-03-05 |
2001-04-10 |
Washington State University Research Foundation |
Methods and composition for the inhibition of cancer cells
|
|
HUP0103314A3
(en)
*
|
1998-08-05 |
2002-07-29 |
Aventis Pharma Sa |
Use of camptothecin derivatives, with reduced gastrointestinal toxicity
|
|
US6043367A
(en)
*
|
1998-09-30 |
2000-03-28 |
Roffler; Steve |
Proactive antitumor compounds
|
|
US20050281821A1
(en)
*
|
1999-01-06 |
2005-12-22 |
Flavia Pernasetti |
Method and composition for angiogenesis inhibition
|
|
US6228855B1
(en)
|
1999-08-03 |
2001-05-08 |
The Stehlin Foundation For Cancer Research |
Aromatic esters of camptothecins and methods to treat cancers
|
|
US6352996B1
(en)
|
1999-08-03 |
2002-03-05 |
The Stehlin Foundation For Cancer Research |
Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
|
|
AU775373B2
(en)
|
1999-10-01 |
2004-07-29 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US6159935A
(en)
*
|
1999-11-29 |
2000-12-12 |
Pharmacia & Upjohn Co. |
Method for preventing diarrhea
|
|
CA2401191C
(en)
|
2000-02-28 |
2006-05-02 |
Aventis Pharma S.A. |
A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
|
|
US6545010B2
(en)
*
|
2000-03-17 |
2003-04-08 |
Aventis Pharma S.A. |
Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
|
|
AR027687A1
(es)
*
|
2000-03-22 |
2003-04-09 |
Yakult Honsha Kk |
Procedimiento para preparar camptotecina
|
|
AU2001261474B2
(en)
|
2000-05-15 |
2006-03-09 |
Celgene Corporation |
Compositions and methods for the treatment of cancer
|
|
EP1286671B1
(en)
*
|
2000-05-15 |
2006-04-05 |
Celgene Corporation |
Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan
|
|
US6486320B2
(en)
|
2000-09-15 |
2002-11-26 |
Aventis Pharma S.A. |
Preparation of camptothecin and of its derivatives
|
|
AU1602902A
(en)
|
2000-10-27 |
2002-05-06 |
Aventis Pharma Sa |
A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
|
|
US7390885B2
(en)
*
|
2001-11-26 |
2008-06-24 |
Cell Matrix, Inc. |
Humanized collagen antibodies and related methods
|
|
US7365167B2
(en)
*
|
2001-11-26 |
2008-04-29 |
Cell Matrix, Inc. |
Humanized collagen antibodies and related methods
|
|
EP2316468A1
(en)
|
2002-02-22 |
2011-05-04 |
Shire LLC |
Delivery system and methods for protecting and administering dextroamphetamine
|
|
JP2005525367A
(ja)
*
|
2002-03-01 |
2005-08-25 |
フアルマシア・イタリア・エツセ・ピー・アー |
塩酸イリノテカンの結晶多形
|
|
CN1649627A
(zh)
*
|
2002-04-26 |
2005-08-03 |
法赫马西亚及普强有限公司 |
用于治疗、预防或延迟肿瘤发生的方法和组合物
|
|
EP1506286B1
(en)
*
|
2002-05-24 |
2014-03-19 |
Merck Sharp & Dohme Corp. |
Neutralizing human anti-igfr antibody
|
|
CN100363366C
(zh)
*
|
2002-06-27 |
2008-01-23 |
中国科学院上海药物研究所 |
一类喜树碱衍生物及制备方法
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
US8034831B2
(en)
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
|
US20040186160A1
(en)
*
|
2002-12-13 |
2004-09-23 |
Sugen, Inc. |
Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
|
|
US7151179B2
(en)
|
2003-05-12 |
2006-12-19 |
Scinopharm Taiwan, Ltd. |
Process for the preparation of 7-alkyl-10-hydroxy-20(S)-camptothecin
|
|
US7067666B2
(en)
*
|
2003-06-27 |
2006-06-27 |
Research Triangle Institute |
7-substituted camptothecin and camptothecin analogs and methods for producing the same
|
|
CZ299329B6
(cs)
*
|
2003-08-26 |
2008-06-18 |
Pliva-Lachema A.S. |
Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu
|
|
TW200526684A
(en)
*
|
2003-11-21 |
2005-08-16 |
Schering Corp |
Anti-IGFR1 antibody therapeutic combinations
|
|
CZ299593B6
(cs)
*
|
2003-12-16 |
2008-09-10 |
Pliva-Lachema A. S. |
Zpusob výroby 7-ethyl-10-hydroxykamptothecinu
|
|
US7700612B2
(en)
*
|
2003-12-23 |
2010-04-20 |
Abraxis Bioscience, Llc |
Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
|
|
DE602005024923D1
(de)
*
|
2004-02-13 |
2011-01-05 |
Yakult Honsha Kk |
Wässrige lösung mit einem camptothecin
|
|
US20070207149A1
(en)
|
2004-04-27 |
2007-09-06 |
Wellstat Biologics Corporation |
Cancer treatment using viruses and camptothecins
|
|
LT3173073T
(lt)
|
2004-05-03 |
2025-01-10 |
Ipsen Biopharm Ltd. |
Liposomos, skirtos vaistų pristatymui
|
|
US20050267141A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Phytogen Life Sciences Inc. |
Process to prepare camptothecin derivatives
|
|
KR100889139B1
(ko)
|
2004-06-01 |
2009-03-17 |
테루모 가부시키가이샤 |
이리노테칸 제제
|
|
US20050272757A1
(en)
*
|
2004-06-04 |
2005-12-08 |
Phytogen Life Sciences Inc. |
Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
|
|
EP3085361A1
(en)
*
|
2004-09-07 |
2016-10-26 |
Biocompatibles UK Limited |
Compositions comprising camptothecins in microspheres
|
|
US7897772B2
(en)
|
2004-10-01 |
2011-03-01 |
Kabushiki Kaisha Yakult Honsha |
Acid addition salt of irinotecan
|
|
US7205385B2
(en)
*
|
2004-11-12 |
2007-04-17 |
General Electric Company |
Polymerization method for the synthesis of polypeptide imaging agents
|
|
CN101146532B
(zh)
|
2005-01-21 |
2012-05-09 |
阿斯泰克斯治疗有限公司 |
药物化合物
|
|
WO2006082053A1
(en)
*
|
2005-02-02 |
2006-08-10 |
Heidelberg Pharma Gmbh |
7-ethyl-10-hydroxy-camptothecin lipid ester derivatives
|
|
WO2006082279A1
(en)
*
|
2005-02-07 |
2006-08-10 |
Fermion Oy |
Process for the manufacturing of 7-ethyl-10-hydroxy camptothecin
|
|
CA2591071C
(en)
*
|
2005-02-08 |
2014-04-29 |
Fermion Oy |
Process for producing [1,4'] bipiperidinyl-1'-carbonyl chloride or hydrochloride thereof
|
|
PL1928883T3
(pl)
|
2005-02-08 |
2014-03-31 |
Fermion Oy |
Sposób otrzymywania chlorowodorku irynotekanu
|
|
WO2006096458A2
(en)
*
|
2005-03-04 |
2006-09-14 |
Novacea, Inc. |
Treatment of hyperproliferative diseases with anthraquinones
|
|
US20070117784A1
(en)
*
|
2005-03-04 |
2007-05-24 |
Novacea, Inc. |
Treatment of hyperproliferative diseases with anthraquinones
|
|
JP4875064B2
(ja)
*
|
2005-04-15 |
2012-02-15 |
シェーリング コーポレイション |
癌を処置または予防するための方法および組成物
|
|
US7994186B2
(en)
*
|
2005-04-18 |
2011-08-09 |
Kabushiki Kaisha Yakult Honsha |
Pharmaceutical compositions containing camptothecins
|
|
US7767200B2
(en)
*
|
2005-07-14 |
2010-08-03 |
Wellstat Biologics Corporation |
Cancer treatment using viruses, fluoropyrimidines and camptothecins
|
|
ZA200800907B
(en)
*
|
2005-07-18 |
2010-04-28 |
Bipar Sciences Inc |
Treatment of cancer
|
|
TW200727900A
(en)
*
|
2005-07-27 |
2007-08-01 |
Yakult Honsha Kk |
Aqueous solution preparation containing camptothecins
|
|
US7608740B2
(en)
*
|
2005-08-03 |
2009-10-27 |
Avra Laboratories Pvt. Ltd |
Method of synthesizing key intermediates for the production of camptothecin derivatives
|
|
JP4994618B2
(ja)
*
|
2005-08-11 |
2012-08-08 |
学校法人北里研究所 |
Ｔｓ−１／カンプトテシン類による化学放射線療法
|
|
US20070048325A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Dennis Van Epps |
Combination therapies for inhibiting integrin-extracellular matrix interactions
|
|
EP2082741A1
(en)
|
2005-09-20 |
2009-07-29 |
Scinopharm Singapore Pte, Ltd. |
Novel crystal form of irinotecan hydrochloride
|
|
US7875602B2
(en)
*
|
2005-10-21 |
2011-01-25 |
Sutter West Bay Hospitals |
Camptothecin derivatives as chemoradiosensitizing agents
|
|
EP1803725A1
(en)
|
2005-12-13 |
2007-07-04 |
W.C. Heraeus GmbH |
Methods for preparing irinotecan
|
|
CN1982313B
(zh)
*
|
2005-12-13 |
2010-12-01 |
深圳市天和医药科技开发有限公司 |
10位取代基上含多个有机羧酸基团的喜树碱化合物及其制法与组合物
|
|
US20070208050A1
(en)
*
|
2006-02-24 |
2007-09-06 |
Palle Venkata Raghavendra Acha |
Process for preparing irinotecan
|
|
CN101033230B
(zh)
*
|
2006-03-10 |
2010-12-08 |
中国科学院上海药物研究所 |
一类喜树碱衍生物及其应用
|
|
AU2007232206B2
(en)
*
|
2006-03-30 |
2013-04-04 |
Drais Pharmaceuticals, Inc. |
Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
|
|
PE20080695A1
(es)
|
2006-04-27 |
2008-06-28 |
Banyu Pharma Co Ltd |
Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
|
|
JP2008081492A
(ja)
|
2006-08-31 |
2008-04-10 |
Banyu Pharmaceut Co Ltd |
オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
|
|
CN101534836B
(zh)
|
2006-09-05 |
2011-09-28 |
彼帕科学公司 |
Parp抑制剂在制备治疗肥胖症的药物中的用途
|
|
WO2008030883A2
(en)
|
2006-09-05 |
2008-03-13 |
Bipar Sciences, Inc. |
Treatment of cancer
|
|
WO2008035229A2
(en)
*
|
2006-09-22 |
2008-03-27 |
Labopharm, Inc. |
Compositions and methods for ph targeted drug delivery
|
|
EA200970353A1
(ru)
*
|
2006-10-06 |
2009-10-30 |
Такеда Фармасьютикал Компани Лимитед |
Комбинированное лекарственное средство
|
|
EP2073807A1
(en)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
WO2008044041A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
US7977336B2
(en)
|
2006-12-28 |
2011-07-12 |
Banyu Pharmaceutical Co. Ltd |
Aminopyrimidine derivatives as PLK1 inhibitors
|
|
US20090062323A1
(en)
*
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched irinotecan
|
|
CN101903025A
(zh)
*
|
2007-10-19 |
2010-12-01 |
彼帕科学公司 |
利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物
|
|
WO2009054332A1
(ja)
|
2007-10-23 |
2009-04-30 |
Banyu Pharmaceutical Co., Ltd. |
ピリドン置換ジヒドロピラゾロピリミジノン誘導体
|
|
US7732491B2
(en)
|
2007-11-12 |
2010-06-08 |
Bipar Sciences, Inc. |
Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
|
|
CA2720184C
(en)
|
2008-03-31 |
2017-07-18 |
Boston Medical Center Corporation |
Predictive marker for topoisomerase i inhibitors
|
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
|
AU2009329872B2
(en)
|
2008-12-23 |
2016-07-07 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
|
PA8855601A1
(es)
|
2008-12-23 |
2010-07-27 |
|
Forformidatos de nucleósidos
|
|
NZ593649A
(en)
*
|
2008-12-23 |
2013-11-29 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
|
AU2010218781A1
(en)
|
2009-02-25 |
2011-07-28 |
Msd K.K. |
Pyrimidopyrimidoindazole derivative
|
|
WO2010101734A1
(en)
|
2009-03-06 |
2010-09-10 |
Merck Sharp & Dohme Corp. |
Combination cancer therapy with an akt inhibitor and other anticancer agents
|
|
EP2896632B1
(en)
|
2009-11-13 |
2017-10-25 |
Daiichi Sankyo Europe GmbH |
Material and methods for treating or preventing HER-3 associated diseases
|
|
US8546573B2
(en)
|
2009-11-18 |
2013-10-01 |
Cadila Healthcare Limited |
Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxy-camptothecin hydrochloride trihydrate
|
|
PT2501413T
(pt)
*
|
2009-11-18 |
2019-07-10 |
Nektar Therapeutics |
Formas de sal de ácido de conjugados de polímero-fármaco
|
|
ES2575160T3
(es)
|
2010-03-15 |
2016-06-24 |
The Board Of Trustees Of The University Of Illinois |
Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
|
|
SG184324A1
(en)
|
2010-03-31 |
2012-11-29 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
US8530444B2
(en)
*
|
2010-06-01 |
2013-09-10 |
Aposense Ltd. |
Pharmaceutical compounds
|
|
WO2012018404A2
(en)
|
2010-08-06 |
2012-02-09 |
U3 Pharma Gmbh |
Use of her3 binding agents in prostate treatment
|
|
WO2012087943A2
(en)
|
2010-12-20 |
2012-06-28 |
The Regents Of The University Of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
WO2013093931A2
(en)
|
2011-09-19 |
2013-06-27 |
Sun Pharma Advanced Research Company Ltd. |
Novel prodrugs of phenolic drugs
|
|
DK2750683T4
(da)
|
2011-10-03 |
2021-04-12 |
Croda Int Plc |
Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser
|
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
|
US9717724B2
(en)
|
2012-06-13 |
2017-08-01 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies
|
|
WO2014070233A1
(en)
|
2012-10-29 |
2014-05-08 |
Boston Medical Center Corporation |
Brca1 mutations as predictive markers for topoisomerase i inhibitors
|
|
CN103848840A
(zh)
*
|
2012-12-03 |
2014-06-11 |
中国人民解放军军事医学科学院毒物药物研究所 |
喜树碱衍生物及其医药用途
|
|
CN103864810A
(zh)
*
|
2012-12-07 |
2014-06-18 |
天津科技大学 |
一种新颖的10-羟基喜树碱10位衍生物制备方法及其在抗肿瘤药物中的应用
|
|
KR101847252B1
(ko)
|
2013-03-27 |
2018-04-09 |
다이호야쿠힌고교 가부시키가이샤 |
이리노테칸염산염 수화물을 함유하는 항종양제
|
|
JP6002835B2
(ja)
|
2013-03-27 |
2016-10-05 |
大鵬薬品工業株式会社 |
低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
|
|
AR095962A1
(es)
|
2013-04-01 |
2015-11-25 |
Moreinx Ab |
Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
|
|
EP2881396A1
(en)
*
|
2013-12-03 |
2015-06-10 |
Synbias Pharma AG |
Method for the synthesis of irinotecan
|
|
JP6704345B2
(ja)
|
2014-01-17 |
2020-06-03 |
オンコラル ファーマ エーピーエス |
癌治療のためのイリノテカンの固体経口剤形
|
|
EA035674B1
(ru)
|
2014-07-18 |
2020-07-24 |
Санофи |
Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
|
|
WO2016123143A1
(en)
|
2015-01-26 |
2016-08-04 |
The University Of Chicago |
CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
|
|
CN107683289B
(zh)
|
2015-01-26 |
2021-08-06 |
芝加哥大学 |
IL13Rα2结合剂和其在癌症治疗中的用途
|
|
US11318131B2
(en)
|
2015-05-18 |
2022-05-03 |
Ipsen Biopharm Ltd. |
Nanoliposomal irinotecan for use in treating small cell lung cancer
|
|
WO2016203352A2
(en)
*
|
2015-06-14 |
2016-12-22 |
Mohan M Alapati |
Compositions and methods for the treatment of cancer
|
|
WO2016203337A2
(en)
*
|
2015-06-14 |
2016-12-22 |
Mohan M Alapati |
Compositions and methods for the treatment of cancer
|
|
KR102293907B1
(ko)
|
2015-06-30 |
2021-08-26 |
한미약품 주식회사 |
이리노테칸 함유 경구용 고형제제 및 그 제조방법
|
|
JP7042739B2
(ja)
|
2015-08-20 |
2022-03-28 |
イプセン バイオファーム リミティド |
癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
|
|
TW202400181A
(zh)
|
2015-08-21 |
2024-01-01 |
英商益普生生物製藥有限公司 |
使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
|
|
AU2016326747A1
(en)
|
2015-09-25 |
2018-03-01 |
Zy Therapeutics Inc. |
Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
|
|
EP4647126A3
(en)
|
2015-10-16 |
2026-02-11 |
Ipsen Biopharm Ltd. |
Stabilizing camptothecin pharmaceutical compositions
|
|
US9980953B2
(en)
*
|
2016-09-26 |
2018-05-29 |
Chong Kun Dang Pharmaceutical Corp. |
Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor
|
|
CN110402163A
(zh)
|
2016-11-02 |
2019-11-01 |
易普森生物制药有限公司 |
使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
|
|
CN108570057A
(zh)
*
|
2017-03-13 |
2018-09-25 |
烟台药物研究所 |
一种合成7-乙基-10-羟基喜树碱的方法
|
|
CA3071599A1
(en)
|
2017-08-07 |
2019-02-14 |
Amgen Inc. |
Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti pd-l1 antibody and an oncolytic virus
|
|
TW202002952A
(zh)
|
2018-03-15 |
2020-01-16 |
美商艾伯維有限公司 |
用於治療胰臟癌之abbv-621與抗癌劑之組合
|
|
WO2019178438A1
(en)
|
2018-03-15 |
2019-09-19 |
Abbvie Inc. |
Abbv-621 in combination with anti-cancer agents for the treatment of cancer
|
|
EP3669890A1
(en)
|
2018-12-18 |
2020-06-24 |
Croda International PLC |
Filamentous nanoparticles having vaccine adjuvant effect
|
|
US20220177583A1
(en)
|
2019-03-20 |
2022-06-09 |
The Regents Of The University Of California |
Claudin-6 bispecific antibodies
|
|
DK3941946T3
(da)
|
2019-03-20 |
2025-03-24 |
Univ California |
Claudin-6-antistoffer og lægemiddelkonjugater
|
|
EP3952841A1
(en)
|
2019-04-09 |
2022-02-16 |
The Board Of Trustees Of The University Of Illinois |
Drug adsorbed highly porous activated carbon for enhanced drug delivery
|
|
JP2022530241A
(ja)
|
2019-04-30 |
2022-06-28 |
インスチトゥート デ メディシーナ モリクラール ジョアン ロボ アントゥネス |
Ｃｄｋ阻害剤と組み合わせたｒａｎｋ経路阻害剤
|
|
EP3962521A1
(en)
|
2019-05-02 |
2022-03-09 |
University of Florida Research Foundation, Inc. |
Compositions for treatment of diffuse intrinsic pontine glioma
|
|
JP7763666B2
(ja)
|
2019-06-24 |
2025-11-04 |
アムジェン インコーポレイテッド |
癌治療のためのＳＩＲＰγの阻害
|
|
CN111171077A
(zh)
*
|
2020-01-19 |
2020-05-19 |
上海交通大学医学院附属仁济医院 |
喜树碱衍生物及其制备方法和应用
|
|
US12521444B2
(en)
|
2021-02-25 |
2026-01-13 |
Fortvita Biologics Limited |
Anti-HER2 antibody-drug conjugates and uses thereof
|
|
IL312728A
(en)
|
2021-11-30 |
2024-07-01 |
Daiichi Sankyo Co Ltd |
Protease-cleavable masked antibodies
|
|
TW202342106A
(zh)
|
2022-02-09 |
2023-11-01 |
日商第一三共股份有限公司 |
環境應答性遮蔽抗體及其利用
|